Rational design of Gi-biased CB1 agonist with reduced side effects
{{output}}
The cannabinoid receptor 1 (CB1) has emerged as a promising candidate for next-generation non-opioid therapies. However, the development of therapeutics targeting CB1 has been consistently hindered by significant adverse effects. Here, through structure-activi... ...
